23andMe: a Risky Healthcare Technology Company With Substantial Upside

Equity Analyst

Dylan Finley

23andMe primarily sells direct-to-consumer personal genome service, or PGS, kits, analyzing specific genetic components (single nucleotide polymorphisms, or SNPs), to approximate genetic ancestry, predisposition to physical traits, and presence of genetic disease variants. The company leverages third party manufacturers for kit components, including the genotype array chip used to analyze the genetic material, and processes the samples on site at LabCorp locations. 12andMe has sequenced the genome of over 12 million individuals, over 80% of whom have opted in to sharing their de-identified genetic data and research survey responses with the company. 23andMe and privately held Ancestry.com hold a dominant share of the direct-to-consumer PGS market due to an early mover advantage, brand awareness, and database size. 

A recent slowdown in kit sales has drawn concerns over the long-term size of the addressable market. As it currently stands, many of the available reports serve more of a novelty purpose, and while the company might identify specific genetic variants corresponding with disease, the SNPs looked at are not comprehensive enough on their own to be a complete substitute for whole genome sequencing (in instances where that is desired by a medical provider). Despite this, the company possesses a massive database of genetic data and an active base of respondents to research questions, which are used to better understand the relationship between the human genome and health characteristics in academic research and commercial drug development. 

The company hopes to use its data to more quickly and efficiently develop therapeutics, particularly in the biotech space, and has attracted interest from manufacturers. In 2018, GlaxoSmithKline made a $300 million equity investment in the company, entering a five-year exclusive collaborative agreement with 23andMe to develop drug candidates. All current candidates are in Phase 1 or preclinical stages of development.

Business Strategy & Outlook

Despite being the pioneer of a model for direct-to-consumer genetic data services, the lack of meaningful barriers to entry in the space and presence of competitor ancestry and health-related gene testing kits preclude the company from establishing an economic moat. 

23andMe primarily generates revenue today through the sale of personal genome service, or PGS, kits. Consumers who purchase a kit provide the company with a saliva sample, from which DNA is isolated. The company uses a technology called genotype imputation, only analyzing a tiny fraction of an individual’s genome, which exhibits known variances in human populations and results in phenotypic (physical characteristic) differences, predisposition to disease, and correlation with other health-related characteristics. In the lab, the genetic material is tested on genotype array chips, which read several hundred thousand single nucleotide polymorphisms, or SNPs, in the sample. Most other competitor DTC companies that offer PGS services use this same process, opting for genotype imputation over whole genome sequencing, due to the very low cost incurred per sample. While whole-genome sequencing has made enormous strides in cost and efficiency since the human genome project was effectively completed in 2003 (13 years of research; costing nearly $3 billion), the cost to sequence a whole genome remains prohibitively high today for most individuals, at around $1000 per sample. By contrast, genotype sampling costs a fraction of that amount. While the technology could follow Moore’s law in the future and become more cost-effective over time, the added benefits of using full genome sequencing in a DTC offering are dubious. Our current state of knowledge of the human genome is extremely limited, and consumers and DTC companies wouldn’t be able to glean any deeper insights as a result of sequencing the whole genome anytime soon. 

To date, over 30 million consumers have used DTC testing kits worldwide, with the vast majority using 23andMe and AncestryDNA (Ancestry.com) over the dozens of smaller competitors. We attribute the high market share concertation between these two companies to superior brand awareness, database size, and availability. Despite, these competitive advantages, two factors preclude us from attributing a moat to the company: (1) a secular decline of kit sales in recent years, confirming fears that the addressable market for PGS is somewhat niche; and (2) the spike in sales around times when genetic testing companies offer steep discounts (for example, Amazon’s Prime Day, winter holiday period) suggests to us that consumers are generally price-sensitive and the company’s pricing power is limited. Furthermore, the company’s primary revenue stream is non-recurring, leaving no room to build up brand loyalty or switching costs within its existing customer base. By contrast, privately owned Ancestry.com has over 3 million subscription-based customers, primarily as a result of their focus on genealogical resources (billions of historical records; hundreds of millions of user generated family trees and user-uploaded photos and documents). While 23andMe has a subscription offering (23andMe+), the added benefits are more marginal than anything--access to several dozen additional disease carrier, wellness, and pharmacogenetic reports. Due to the static nature of these reports (our genome is fixed and reports shouldn’t change), future engagement is limited to instances where the company releases new genetic reports. Consequently, these incremental reports must be compelling enough on their own to move consumers over to this recurring subscription model. 

From a cost advantage or intangible assets standpoint, 23andMe does not have any material competitive advantages in sequencing customers’ genetic data. Similar to other DTC competitors, 23andMe relies on various third parties and labs. The genotyped samples are analyzed at Labcorp facilities in the U.S., using Illumina’s global screening array chip as a base (with some added SNPs of interest). While additional scale allows for the company to achieve a degree of leverage on operating expenses, and contracts with suppliers allow for advantageous pricing based on volume, these benefits are conferred to any kit seller generating meaningful volume. Furthermore, while the company is on the cutting edge of generating actionable insights based off genetic data (that is pharmacogenetic reports), its unclear at this time how valuable these reports are to consumers and whether this will translate into recurring business. For consumers who are primarily interested in the novelty aspect of sequencing their DNA (tracing their predicted roots; viewing trait reports), more detailed health related reports may not be of sufficient interest for consumers to upgrade to the latest version of a chip or pay a premium versus competitors’ offerings. As such, despite any advantage stemming from superior research, the company may continue to act more as a price taker, similar to most other kits on the market

23andMe entered the telehealth space in 2021, with its $400 million acquisition of Lemonaid. The standalone company generates around $60 million in revenue, on an annualized basis from the quarter the deal closed. From a strategic standpoint, the company sees the acquisition as a route to get from consumer genetics services to individualized health care. The status quo for primary care today does not take into account a patient’s genetic data (except in select rare disease cases), and 23andMe sees itself bridging this gap. Our primary concern is the disconnect between the company’s goals and Lemonaid’s offerings as of today. Lemonaid connects consumers with medical professionals via telehealth and delivers select prescription drugs to consumers via mail. The company’s focus is on treatment areas which patients may not actively be seeking out due to stigma (mental health, men and women’s reproductive health). Lemonaid offers primary care services via a monthly fee, which is not reimbursed by medical insurance. In the near-term, the acquisition does not provide for any meaningful synergies or enhance the competitive positioning of the company’s PGS business. From a primary care perspective, the company’s primary challenge will be educating telehealth providers on offering a new type of health care which combines traditional care tailored to specific genetic insights. 

Lastly, the company’s therapeutics segment is too far in its infancy for us to consider and economic moat. The company has dozens of drug candidates in very early development stages and is still several years away from having a commercially viable therapy. The value proposition of using genetic inferences to most efficiently find targets (particularly in the realm of biologics), is of high interest to biopharma firms. The company’s five-year agreement with GlaxoSmithKline currently has the company locked in an exclusive arrangement through 2023, after which we could see the company taking on several partners on a nonexclusive basis. We are a bit hesitant of the company’s ability to develop and take to market a drug on their own at this stage due to the capital intensity. While 23andMe has a large amount of cash on its balance sheet, the cash flow dilutive nature of its core business, and the company could get more value in the near term by continuing with 50/50 partnerships or by electing to take royalties from collaborative projects.

None

Economic Moat

23andMe

23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA.

GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using  23andMe's proprietary genetic and health survey database

23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program

The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutation The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutation

23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker

23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells

23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors

SUNNYVALE, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the results of the completed redemption (the “Redemption”) of all of its outstanding warrants (the “Warrants”) to purchase shares of Class A common stock of 23andMe that were issued under the Warrant Agreement, dated October 1, 2020 (the “Warrant Agreement”), by and between 23andMe and Continental Stock Transfer & Trust Company, as warrant agent. The Warrants include the public warrants (the “Public Warrants”) issued as part of the units sold in the initial public offering (the “IPO”) of 23andMe, which was formerly known as VG Acquisition Corp., and the private warrants that were sold in a private placement simultaneously with the IPO.

23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants

Medpace Holdings

Mesa Laboratories

These smaller healthcare companies all have 10x potential for investors.

My 3 Favorite Under-the-Radar Healthcare Stocks for 2022

GlaxoSmithKline

These two companies have massive growth opportunities and have declined sharply in recent months.

2 Cheap Stocks With 10X Potential to Buy in 2022

Airbnb

Legalzoom.com

3 Top IPO Stocks to Put on Your Watchlist

Poshmark

Riskified Ltd

With these kinds of resources, these companies are becoming less-risky investments.

Like Strong Balance Sheets? These 3 Stocks Are Loaded With Cash

The company reported disappointing earnings results and has fallen victim to the recent sell-off in high-growth stocks.

Why 23andMe Stock Dropped 29% in November

Her genetics testing company is the latest to flounder after going public via SPAC.

Anne Wojcicki's 23andMe Fortune Falls Under $1 Billion As Shares Sink Post-IPO

Dr. Arron brings nearly two decades of scientific leadership in biotech drug discovery and development to 23andMe's Therapeutics team Dr. Arron brings nearly two decades of scientific leadership in biotech drug discovery and development to 23andMe's Therapeutics team

23andMe Announces the Appointment of Joseph R. Arron, M.D.

SUNNYVALE, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it will redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of Class A common stock of 23andMe that were issued under the Warrant Agreement, dated October 1, 2020 (the “Warrant Agreement”), by and between 23andMe and Continental Stock Transfer & Trust Company, as warrant agent (the “Warrant Agent”), as part of the units sold in the initial public offering (the “IPO”) of 23andMe, which was formerly known as VG Acquisition Corp., and that remain outstanding at 5:00 p.m. New York City time on December 22, 2021 (the “Redemption Date”) for a redemption price of $0.10 per Public Warrant. In addition, 23andMe will redeem all of its outstanding warrants to purchase Class A common stock that were issued under the Warrant Agreement in a private placement simultaneously with the IPO (the “Private Warrants” and, together with the Public Warrants, the “Warrants”) on the same terms as the outstanding Public Warrants.

23andMe Announces Redemption of All Outstanding Warrants

23andMe recently reported quarterly results which held no major surprises as the company continues to build out its DNA-based reports available to consumers.

23andMe: No Surprises With Recent Earnings, But Long-Term Story Remains Positive

Last week's good news for the genetic data miner wasn't as good as it looked.

Why 23andMe Stock Crashed 10% Today

23andMe lost a lot less money than feared today -- so why is it sticking with a prediction for a full-sized loss for the year?

Why 23andMe Stock Scored an 11% Gain Today

23andMe Holding Co. (ME) CEO Anne Wojcicki on Q2 2021 Results - Earnings Call Transcript

Second quarter revenue of $55 million Recent addition of telemedicine platform further advances vision of individualized primary care that empowers consumers to live healthier lives

23andMe Reports FY2022 Second Quarter Financial Results

SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, announced today that management will be presenting at three upcoming virtual investor conferences: Credit Suisse 30th Annual Healthcare Conference on Thursday, November 11 at 12:10 pm ET Piper Sandler 33rd Annual Healthcare Conference.

23andMe to Present at Upcoming Virtual Healthcare Conferences

SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, today announced the appointment of Dr. Sandra Hernández, President & CEO of the California Health Care Foundation ("CHCF"), to its Board of Directors.

23andMe Announces Appointment of Dr. Sandra Hernández to Board of Directors

Coinbase

Plug Power

Nearly 500 companies are reporting quarterly earnings this week. The one in our watch list for Monday morning, Coty, beat estimates on both the top and bottom lines.

Earnings Previews: Coinbase, Nio, Plug Power, 23andMe

SUNNYVALE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 second quarter after market closes on Wednesday, November 10, 2021.

23andMe Provides Updated Timing for FY2022 Second Quarter Financial Results and Announces New Online Q&A Platform for Shareholders

The genetics upstart is acquiring a telehealth platform.

Why 23andMe Rocketed 27.9% Higher in October

SUNNYVALE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it has completed its previously-announced acquisition of Lemonaid Health, Inc. (“Lemonaid Health”), an on-demand platform for accessing medical care and pharmacy services online.

23andMe Announces the Closing of its Acquisition of Lemonaid Health

Investors may see potential in the company's proposed acquisition of telehealth company Lemonaid.

Why 23andMe Stock Was Up More Than 9% on Tuesday

Hims & Hers Health has had its biggest one-day loss in over two months, following its rival 23andMe's agreement to buy web-based healthcare platform Lemonaid Health. Hims & Hers is a telehealth platform working on custom health and wellness in multi-specialty needs.

News for 23andMe Stock (ME)